REGISTERED NUMBER: 07925414 (England and Wales)

Unaudited Financial Statements

for the Year Ended 31 January 2018

for

Stablepharma Limited

Contents of the Financial Statements for the Year Ended 31 January 2018

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

Stablepharma Limited

Company Information for the Year Ended 31 January 2018

DIRECTORS: N E Child Dr B J Roser

M C Powell R J Shepherd

SECRETARY: Ms N J Smith

REGISTERED OFFICE: Lennox House

3 Pierrepont Street

Bath BA1 1LB

REGISTERED NUMBER: 07925414 (England and Wales)

Stablepharma Limited (Registered number: 07925414)

Balance Sheet 31 January 2018

		2018		2017 as restated	
	Notes	£	£	£	£
FIXED ASSETS					
Intangible assets	4		142,034		120,066
Tangible assets	5		503		744
-			142,537		120,810
CURRENT ASSETS					
Debtors	6	1,385		3,273	
Cash at bank		34,040		362	
		35,425		3,635	
CREDITORS					
Amounts falling due within one year	7	_572,037_		<u>493,463</u>	
NET CURRENT LIABILITIES			(536,612)		_(489,828)
TOTAL ASSETS LESS CURRENT					
LIABILITIES			(394,075)		<u>(369,018</u>)
CAPITAL AND RESERVES					
Called up share capital			5,541		5,450
Share premium			213,551		-
Retained earnings			(613,167)		(374,468)
~			(394,075)		(369,018)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2018 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
 - preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of
- (b) Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 11 October 2018 and were signed on its behalf by:

N E Child - Director

Stablepharma Limited (Registered number: 07925414)

Notes to the Financial Statements for the Year Ended 31 January 2018

1. STATUTORY INFORMATION

Stablepharma Limited is a private company. limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents are being amortised evenly over their estimated useful life of nil years.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 25% on straight line basis

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2017 - NIL).

Page 3 continued...

Stablepharma Limited (Registered number: 07925414)

Notes to the Financial Statements - continued for the Year Ended 31 January 2018

4. INTANGIBLE FIXED ASSETS

4.	INTANGIBLE FIXED ASSETS		Other intangible
			assets £
	COST At 1 February 2017		120,066
	Additions		21,968
	At 31 January 2018		142,034
	NET BOOK VALUE		4.40.004
	At 31 January 2018		142,034
	At 31 January 2017		120,066
5.	TANGIBLE FIXED ASSETS		
			Computer
			equipment
	COST		£
	At 1 February 2017		
	and 31 January 2018		965
	DEPRECIATION		
	At 1 February 2017		221
	Charge for year At 31 January 2018		<u>241</u> 462
	NET BOOK VALUE		402
	At 31 January 2018		503
	At 31 January 2017		744
6.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	2018	2017
		2016	as restated
		£	£
	VAT	<u>1,385</u>	<u>3,273</u>
-	OPERITORS, AMOUNTS FALLING BUE WITHIN ONE VEAR		
7.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	2018	2017
		2010	as restated
		£	£
	Trade creditors	291,307	205,232
	Tax	(7,346)	-
	Other creditors Accruals and deferred income	285,031 3,045	285,031 3,200
	Accidate and deterred income	572,037	493,463
		<u> </u>	

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.